Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | MTOR | P42345 | 2/20 | 0.90 |
| ▸ | THRB | P10828 | 1/20 | 0.90 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.90 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.90 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL1201153 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL376514 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL28898416 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL9007590 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL39902 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL285195 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL104628 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL6672407 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL29084328 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL2370482 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60089423-A | — | — | None | — | — | JP | disclosed |
| EP-3429570-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | ORYZON GENOMICS SA (ES) | 2026-05-20 | — | — | EP | disclosed |
| US-12594293-B2 | Use of 6-thio-dG to treat therapy-resistant telomerasepositive pediatric brain tumors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260034116-A1 | CANCER COMBINATION THERAPY INCLUDING A BCL-2 INHIBITOR | RYVU THERAPEUTICS S A (PL) | 2026-02-05 | — | — | US | disclosed |
| US-12516302-B2 | DNA polymerase theta mutants, methods of producing these mutants, and their uses | INSTITUT PASTEUR (FR) | 2026-01-06 | — | — | US | disclosed |
| EP-4561578-A1 | CANCER COMBINATION THERAPY INCLUDING A BCL-2 INHIBITOR | Ryvu Therapeutics S.A. (PL) | 2025-06-04 | — | — | EP | disclosed |
| CN-117599186-B | Pharmaceutical use of LAPTM5 inhibiting substances in AML | 中山大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-119836291-A | Combination therapy for cancer comprising BCL-2 inhibitors | 雷沃医疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119818525-A | Cytarabine amino acid ester composition and application thereof | 沈阳信达泰康医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119638765-A | Cytarabine Process for preparing glycoside | 江苏香地化学有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20090004138-A1 | Bicyclic Nucleosides and Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-01-01 | — | — | US | disclosed |
| EP-1858889-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-11-28 | — | — | EP | disclosed |
| CN-100999540-A | Tech, of producing cytidine by chemical synthesizing process | UNIV HENAN NORMAL (CN) | 2007-07-18 | — | — | CN | disclosed |
| WO-2006094347-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2006-09-14 | — | — | WO | disclosed |
| EP-0918534-A4 | PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME | UNIV PITTSBURGH (US) | 2001-10-10 | — | — | EP | disclosed |
| US-5952294-A | OLIGOPEPTIDE ATTACHED TO AMINO, HYDROXY OR THIOL FUNCTIONS OF THERAPEUTIC AGENT, E.G. ARA-C, TO EXTEND ITS BIOLOGICAL ACTIVE LIVE IN VIVO; CONTROLLING THE KINETICS AND METABOLISM; LEUKEMIA; VIRICIDES; ANTITUMOR/-CARCINOGENIC AGENTS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0918534-A1 | PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998004277-A1 | PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1998-02-05 | — | — | WO | disclosed |
| JP-S6089423-A | CARCINOSTATIC AGENT | SATO HARUO | 1985-05-20 | — | — | JP | disclosed |
| JP-S0689423-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004138-A1 | Bicyclic Nucleosides and Nucleotides as Therapeutic Agents | SLC29A2, NT5C2, NUDT1 | LMNA 1105/4885MTOR 1811/4885THRB 4094/4885 |
| US-12594293-B2 | Use of 6-thio-dG to treat therapy-resistant telomerasepositive pediatric brain tumors | POT1, TERF2, TERT | LMNA 2377/4885MTOR 812/4885THRB 388/4885 |
| US-20260034116-A1 | CANCER COMBINATION THERAPY INCLUDING A BCL-2 INHIBITOR | BBC3, BCL3, MCL1 | LMNA 1862/4885MTOR 1784/4885THRB 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.